Literature DB >> 20501475

A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women.

David Conen1, Paul M Ridker, Brendan M Everett, Usha B Tedrow, Lynda Rose, Nancy R Cook, Julie E Buring, Christine M Albert.   

Abstract

AIMS: To assess the joint influence of inflammatory biomarkers on the risk of incident atrial fibrillation (AF) in women. METHODS AND
RESULTS: We performed a prospective cohort study among women participating in the Women's Health Study. All women were free of AF at study entry and provided a baseline blood sample assayed for high-sensitivity C-reactive protein, soluble intercellular adhesion molecule-1, and fibrinogen. To evaluate the joint effect of these three biomarkers, an inflammation score was created that ranged from 0 to 3 and reflected the number of biomarkers in the highest tertile per individual. During a median follow-up of 14.4 years, 747 of 24,734 women (3.0%) experienced a first AF event. Assessed individually, all three biomarkers were associated with incident AF, even after adjustment for traditional risk factors. When combined into an inflammation score, a strong and independent relationship between inflammation and incident AF emerged. Across increasing inflammation score categories, there were 1.66, 2.22, 2.73, and 3.25 AF events per 1000 person-years of follow-up. The corresponding hazard ratios (95% confidence intervals) across inflammation score categories were 1.0, 1.22 (1.00-1.49), 1.32 (1.06-1.65), and 1.59 (1.22-2.06) (P for linear trend 0.0006) after multivariable adjustment.
CONCLUSION: In this large-scale prospective study among women without a history of cardiovascular disease, markers of systemic inflammation were significantly related to AF even after controlling for traditional risk factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501475      PMCID: PMC2903714          DOI: 10.1093/eurheartj/ehq146

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  34 in total

1.  Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study.

Authors:  Kenneth J Mukamal; Janne S Tolstrup; Jens Friberg; Gorm Jensen; Morten Grønbaek
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

2.  Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Douglas Packer; Allan Skanes
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

Review 3.  A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need.

Authors:  Albert L Waldo
Journal:  Am Heart J       Date:  2006-04       Impact factor: 4.749

4.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

5.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation.

Authors:  A Frustaci; C Chimenti; F Bellocci; E Morgante; M A Russo; A Maseri
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

6.  Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

Authors:  P M Ridker; C H Hennekens; B Roitman-Johnson; M J Stampfer; J Allen
Journal:  Lancet       Date:  1998-01-10       Impact factor: 79.321

7.  C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization.

Authors:  Bernard Lo; Rob Fijnheer; Arno P Nierich; Peter Bruins; Cor J Kalkman
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

8.  Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation.

Authors:  John Dernellis; Maria Panaretou
Journal:  Am J Cardiol       Date:  2005-11-28       Impact factor: 2.778

9.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

10.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

View more
  43 in total

1.  Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation.

Authors:  David Conen; Jorge A Wong; Roopinder K Sandhu; Nancy R Cook; I-Min Lee; Julie E Buring; Christine M Albert
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

Review 2.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

3.  Relation of renal function to risk for incident atrial fibrillation in women.

Authors:  Roopinder K Sandhu; Tobias Kurth; David Conen; Nancy R Cook; Paul M Ridker; Christine M Albert
Journal:  Am J Cardiol       Date:  2011-11-17       Impact factor: 2.778

Review 4.  Impact of Atrial Fibrillation On Cardiovascular Mortality in the Setting of Myocardial Infarction.

Authors:  Mahmoud Suleiman; Doron Aranson
Journal:  J Atr Fibrillation       Date:  2012-12-16

5.  Predictors of non-pulmonary vein foci in paroxysmal atrial fibrillation.

Authors:  Keita Watanabe; Junichi Nitta; Osamu Inaba; Akira Sato; Yukihiro Inamura; Nobutaka Kato; Masahito Suzuki; Masahiko Goya; Kenzo Hirao; Tetsuo Sasano
Journal:  J Interv Card Electrophysiol       Date:  2020-05-28       Impact factor: 1.900

6.  Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and an electrochemiluminescense-based multi-array platform.

Authors:  Bas C T van Bussel; Isabel Ferreira; Marjo P H van de Waarenburg; Marleen M J van Greevenbroek; Carla J H van der Kallen; Ronald M A Henry; Edith J M Feskens; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

7.  Risk factors for incident atrial fibrillation with and without left atrial enlargement in women.

Authors:  David Conen; Robert J Glynn; Roopinder K Sandhu; Usha B Tedrow; Christine M Albert
Journal:  Int J Cardiol       Date:  2013-01-17       Impact factor: 4.164

8.  B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.

Authors:  Moritz F Sinner; Katherine A Stepas; Carlee B Moser; Bouwe P Krijthe; Thor Aspelund; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Ramachandran S Vasan; Thomas J Wang; Sunil K Agarwal; David D McManus; Oscar H Franco; Xiaoyan Yin; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Brad C Astor; Christie M Ballantyne; Ron C Hoogeveen; Andrew E Arai; Elsayed Z Soliman; Patrick T Ellinor; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Michael J Pencina; Emelia J Benjamin; Alvaro Alonso
Journal:  Europace       Date:  2014-07-18       Impact factor: 5.214

9.  The risk of atrial fibrillation in patients with rheumatoid arthritis.

Authors:  Seoyoung C Kim; Jun Liu; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

10.  Type 2 diabetes mellitus and risk of incident atrial fibrillation in women.

Authors:  Tobias Schoen; Aruna D Pradhan; Christine M Albert; David Conen
Journal:  J Am Coll Cardiol       Date:  2012-09-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.